ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0107

Screening for Non-criteria Antiphospholipid Autoantibodies in Patients Younger Than 50 Years Old Admitted for Venous Thromboembolism: A Cross-sectional Study
Abstract Number: 0195

Screening for Social Determinants of Health in Patients with SLE: A Point-of-Care Feasibility Study
Abstract Number: 0934

Screening NLRP3 Drug Candidates in Clinical Development:Lessons from Existing and Emerging Technologies
Abstract Number: 0956

Secreted Frizzled-Related Protein 2 (sFRP2) Regulates Wnt Signaling to Affect Mesenchymal Transition of Lung Epithelial Cells Participates in Interstitial Lung Disease
Abstract Number: 2344

Secukinumab Retention and Effectiveness in Patients with Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: 5-year Final Results of a Prospective Real-world Study
Abstract Number: 0793

Secular Changes in Widespread Pain Across Two Generations: The Framingham Heart Study
Abstract Number: 0604

Secular Trends in Biologic Prescribing for Psoriasis and Psoriatic Arthritis, 2014-2024
Abstract Number: 1786

Select Immune Cell Dysregulation Identifies Clinically Quiescent Patients at Risk of Flare Who Stop Mycophenolate Mofetil While Continuing Hydroxychloroquine
Abstract Number: 0623

Select Patient Reported Outcome Measure Domains Enhance Immune Mediator Based Indexes That Inform Flare Risk and Disease Activity in Systemic Lupus Erythematosus
Abstract Number: 1849

Selective Targeting of One-Carbon Metabolism to Combat Rheumatoid Arthritis
Abstract Number: 0246

Selectively Targeting TRBV11-2+ T Cells in Multisystem Inflammatory Syndrome in Children (MIS-C) Using Bispecific T Cell-Engaging Antibodies
Abstract Number: 0073

Self or Bacteria-reactive Th17 Expand from Conventional and Regulatory T Cells in Parabacteroides Goldsteinii Gnotobiotic Arthritic SKG Mice, in Context of Interferon-driven Synovial Inflammatory Macrophages and Reduced Bacterial Immune Regulation
Abstract Number: 2071

Self-Efficacy Contributes to Better Health Outcomes in Patients of Idiopathic Inflammatory Myopathies: Insights from the COVAD 3 Dataset
Abstract Number: 1048

Self-Perception of Oral Health and Habits in Patients with Sjögren’s Syndrome, Rheumatoid Arthritis, and Systemic Lupus Erythematosus
Abstract Number: 1491

Self-Reported Cognitive Function Among Older Adults with Systemic Lupus Erythematosus (SLE) Compared to Older Adults with Other Rheumatic and Musculoskeletal Conditions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].